

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Schoeberl Birgit M.</u>  (Last) (First) (Middle) <u>C/O MERRIMACK</u> <u>PHARMACEUTICALS, INC.</u> <u>ONE KENDALL SQUARE, SUITE B7201</u>  (Street) <u>CAMBRIDGE MA</u> <u>02139</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/30/2015</u>	3. Issuer Name and Ticker or Trading Symbol <u>MERRIMACK PHARMACEUTICALS INC [ MACK ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below)  <u>Head of Discovery</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,600	D	

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	08/03/2015	Common Stock	30,000	1.71	D	
Stock Option (right to buy)	(1)	09/22/2018	Common Stock	12,234	1.81	D	
Stock Option (right to buy)	(1)	11/05/2019	Common Stock	78,000	2.12	D	
Stock Option (right to buy)	(1)	08/01/2016	Common Stock	50,000	2.12	D	
Stock Option (right to buy)	(1)	10/04/2017	Common Stock	50,000	2.12	D	
Stock Option (right to buy)	(1)	10/15/2020	Common Stock	50,000	2.69	D	
Stock Option (right to buy)	(1)	05/03/2021	Common Stock	30,000	5.54	D	
Stock Option (right to buy)	(2)	08/22/2022	Common Stock	33,500	7.53	D	
Stock Option (right to buy)	(3)	03/11/2023	Common Stock	100,000	6.35	D	
Stock Option (right to buy)	(4)	02/10/2024	Common Stock	75,000	5.02	D	

Explanation of Responses:

- 1. This option is fully vested.
- 2. This option vested as to 1/12th of the total number of shares on 11/23/12 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 8/23/15.
- 3. This option vested as to 1/12th of the total number of shares on 6/12/13 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 3/12/16.
- 4. This option vested as to 1/12th of the total number of shares on 5/11/14 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/11/17.

/s/ Jeffrey A. Munsie, attorney-  
in-fact 02/06/2015

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.